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ABSTRACT: Traumatic brain injury (TBI) is a leading cause of death and disability
worldwide. TBI can have a long-term impact on the quality of life for survivors of all ages.
However, there remains no approved treatment that improves outcomes following TBI,
which is partially due to poor delivery of therapies into the brain. Therefore, there is a
significant unmet need to develop more effective delivery strategies that increase the
accumulation and retention of potentially efficacious treatments in the injured brain.
Recent work has revealed that nanoparticles (NPs) may offer a promising approach for
site-specific delivery; however, a detailed understanding of the specific NP properties that
promote brain accumulation and retention are still being developed. Multimodal imaging plays a vital role in the understanding of
physicochemical properties that initiate the uptake and accumulation of NPs in the brain at both high spatial (e.g., fluorescence
imaging) and temporal (e.g., magnetic resonance imaging, MRI) frequency. However, many NP systems that are currently used in
TBI only provide contrast in a single imaging modality limiting the imaging data that can be obtained, and those that offer
multimodal imaging capabilities have complicated multistep synthesis methods. Therefore, the goal of this work was to develop an
ultrasmall NP with simple fabrication capable of multimodal imaging. Here, we describe the development, characterization,
accumulation, and retention of poly(ethylene glycol) (PEG)-coated europium−gadolinium (Eu−Gd) mixed magnetic NPs (MNPs)
in a controlled cortical impact mouse model of TBI. We find that these NPs having an ultrasmall core size of 2 nm and a small
hydrodynamic size of 13.5 nm can be detected in both fluorescence and MR imaging modalities and rapidly accumulate and are
retained in injured brain parenchyma. These NPs should allow for further testing of NP physicochemical properties that promote
accumulation and retention in TBI and other disease models.
1. INTRODUCTION
Traumatic brain injury (TBI) results from a trauma that causes
sudden damage to the brain. TBI causes approximately 2.87
million annual reported deaths, hospitalizations, and emer-
gency room visits in the United States alone.1 Primary injury
occurs as a direct result of mechanical trauma that results in
the displacement and/or physical contusioning of the brain
leading to intracranial hematomas, skull fractures, lacerations,
contusions, and penetrating wounds. Secondary brain injury
arises from the complications of the primary injury including
necrotic cell death, oxidative stress, and damage to the blood−
brain barrier (BBB) and leads to the secondary spread of
damage into the surrounding brain, which can lead to
progressive neurodegenerative diseases.2−4 Secondary injury
continues in the hours, days, and even years following the
primary injury.5−8 Therefore, this secondary injury cascade is
the target for therapy development to help minimize the
spread of damage.9−11 Several clinical trials have attempted to
minimize secondary processes that cause additional damage
following TBI. Unfortunately, no strategy has been successful
so far in humans. At present, only limited supportive care
therapies are available to TBI patients.
Nanoparticles (NPs) can play a significant role in the
imaging and treatment of TBI.12,13 The improvement of NPs
for therapeutic uses has been continuing for decades.14 Several
nanomaterials have been studied for TBI, and they are mostly
antioxidant NPs, which contain functional groups that can
deactivate reactive oxygen species (ROS).15−19 For example,
superoxide dismutase (SOD)-coated NPs were synthesized to
minimize the oxidative stress-mediated neuronal damage,17
carbon particles were used as antioxidant treatment for
TBI,16,20 and thioether polymer and core-cross-linked NPs
have been shown to reduce post-traumatic neurodegeneration,
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neuroinflammation, and improve the outcome.15,19 However,
the physicochemical properties of NPs that promote
accumulation and retention in the injured brain are still
being developed.21 While NP properties and behaviors have
been widely studied in the context of cancer, knowledge on
how these properties affect their ability to accumulate and be
retained in TBI are still in the early stages. The size of a NP
and administration time following the injury seem to play a
major role in accumulation and retention,22−24 but there is still
a wide range of NP properties that remain unstudied such as
surface charge, shape, and surface chemistry including possible
active targeting mechanisms. An NP-based tool that will allow
for imaging through multiple imaging modalities would
provide a framework for these properties to be studied. We
have recently developed an MR imaging method to assess the
accumulation and retention kinetics of various NPs in TBI.22
However, an NP system with a simple synthesis scheme that
can be used for both MR and fluorescence imaging is still
needed to achieve both high temporal and high spatial
resolution imaging of the NP behavior in TBI.
Mixed lanthanide oxide magnetic NPs (MNPs) are desirable
because they have both inherent paramagnetic and fluorescent
properties, which are significantly useful for dual imaging.25
Mixed MNPs have an advantage over heterojunction, core−
shell, and dye-coated NPs because of their robustness, stability,
compactness, and compositionally controlled synthesis proce-
dure. Furthermore, magnetic and fluorescent properties are
minimally affected by surface coating due to the compactness
of 4f orbitals close to the nucleus.26 Additionally, a small
particle diameter enhances fluorescence intensities because the
reduced excitation migration to quenching sites is proportional
to the particle diameter.27,28 Biocompatible ligand-coated
MNPs provide a promising option to gain insight into ideal
NP properties as their size, shape, and surface properties can
be tuned. Furthermore, MNPs offer the ability to be imaged
through multiple imaging modalities to provide both high
temporal and spatial resolution imaging to identify uptake and
retention kinetics as well as cellular distribution to gain a better
understanding of brain delivery.29 Here, we describe, for the
first time, the development and use of mixed lanthanide oxide
MNPs containing europium (Eu) for fluorescence imaging and
gadolinium (Gd) for MR imaging in TBI. Looking forward,
these MNPs could be coated with different length poly-
(ethylene glycol) (PEGs) to alter their hydrodynamic size,
heterobifunctional PEGs (e.g., carboxyl and amine) to alter the
surface charge, and functionalized with targeting agents to
better study how physicochemical properties affect accumu-
lation and retention in TBI.
2. RESULTS AND DISCUSSION
It is required to coat the NPs with a biocompatible and water-
soluble ligand for biomedical applications. The addition of
PEG to NP surfaces reduces the reticuloendothelial system
(RES) uptake and increases circulation time.30−32 PEG coating
also shields the surface from aggregation, and the solubility in
serum increases because of repeating the hydrophilic ethylene
glycol units.33,34 PEG diacid was used in this work. The high-
resolution transmission electron microscopy (HRTEM)
images of PEG diacid-coated Eu−Gd NPs are shown in
Figure 1a. The average particle diameter is around 2.1 nm
verifying their ultrasmall core size. High-angle annular dark-
field scanning transmission electron microscopy (HAADF-
STEM) was also measured to validate the presence of both Eu
and Gd in the NPs. As HAADF-STEM is correlated to the
atomic mass, we were able to determine the presence of Eu,
Gd, and O in the mixed Eu−Gd NP system (Figure 1b). From
these measurements and inductively coupled plasma mass
spectrometry (ICP-MS), we determined that the final ratio of
Eu and Gd in the NPs was the same as the feed ratio. We
synthesized Eu−Gd (25−75%), Eu−Gd (50−50%), and Eu−
Gd (75−25%) NPs. From dynamic light scattering (DLS)
measurement, the average hydrodynamic size of the nano-
particle was 13.5 nm (Figure 1c), and ζ-potential was −25.1
mV (Figure 1d) in Dulbecco’s phosphate-buffered saline
(DPBS) (pH 7.4). Surface modification of nano-drug delivery
systems is the most common strategy for controlling the
opsonization process and thus sustain the systems for a longer
period in the bloodstream.35 The negative ζ-potential provides
increased passivation by preventing adsorption by negatively
charged serum proteins, reduced agglomeration, and promot-
ing distribution into the tissue.36 The PEG diacid coating was
confirmed after Fourier transform-infrared (FT-IR) spectros-
copy. We compared PEG diacid-coated Eu−Gd NPs with free
PEG diacid and observed that the CO stretch was red-
shifted by ∼140 cm−1 from that (=1736 cm−1) of a free PEG
diacid (Figure 1e), confirming the attachment of the −COOH
group to the NPs as commonly observed in metal oxide NPs
coated with the −COOH group containing ligands.37,38 The
broad peak at around 3400 cm−1 corresponds to the −OH
groups.
To determine the fluorescence properties of the NPs, we
generated an excitation−emission matrix. We investigated
excitation from 250 to 700 nm and corresponding emission
wavelengths (300 to 700 nm). From the two-dimensional
excitation−emission (2D Ex−Em) matrix, a maximum
fluorescent signal for the synthesized Eu−Gd NPs was
observed using excitation and emission wavelengths of 365
and 450 nm, respectively (Figure 2a). We also investigated the
fluorescence of different compositions of Eu−Gd NPs to
identify the maximum intensity containing Eu−Gd NPs. We
found that Eu−Gd (75−25%) showed the maximum
fluorescence intensity (Figure 2b), which is expected because
Eu is responsible for the majority of the fluorescence in the
NPs.
Figure 1. (a) HRTEM images of the PEG diacid-coated ultrasmall
Eu−Gd nanoparticles. The corresponding circle shows the diameter
of the nanoparticle, which is 2.1 nm (n = 71). (b) High-angle annular
dark-field scanning transmission electron microscopy (HAADF-
STEM) image and element mapping [Gd (green), Eu (red), O
(blue)] of Eu−Gd NPs. (c) From DLS, the average size of the
nanoparticle is 13.5 nm. (d) ζ-potential value is −25.1 mM for the
Eu−Gd nanoparticles. (e) FT-IR absorption spectra of (I) free PEG
diacid (black line), (II) PEG diacid-coated ultrasmall Eu−Gd
nanoparticles (red line).
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We also tested the fluorescence lifetime of the NPs since
many lanthanides including Eu39,40 are commonly used in
fluorescence lifetime imaging studies.41 However, the fluo-
rescence lifetime of the NPs of 1.6 ns (Table 1) is very close to
the lifetime of cell autofluorescence42 of around 2 ns,43,44 and
is not extended as observed with other Eu-based imaging
agents.39,40 This is likely because the extended lifetime afforded
by Eu is a result of chelation to specific ligands that enhance
the fluorescence lifetime of Eu, which were not on the NP.
Therefore, different polymeric coatings for these NPs are likely
needed to take advantage of fluorescence lifetime imaging
capabilities. Furthermore, other lanthanides could be included
to tune the photophysical properties of the MNPs to achieve
desired luminescent lifetimes41 or upconversions45 for
enhanced brightness and depth of imaging.46
To determine the magnetic resonance imaging (MRI)
enhancing properties of the NPs, both R1 and R2 were
measured at 9.4 T and plotted as a function of Ln (Ln = Gd
and Eu) concentration. Three different ratios of the Eu−Gd
sample were measured and are shown in Figure 3a. The
highest relaxivities were observed for Eu−Gd (25−75%),
which was expected as Gd is responsible for the majority of
MRI contrast in the NPs. Longitudinal (r1) water proton
relaxivities were estimated from the corresponding slopes,
giving a value of 7.11 s−1 mM−1 for Eu−Gd (25−75%). The r1
relaxivities were 4.77 and 1.66 s−1 mM−1 for Eu−Gd (50−
50%) and Eu−Gd (75−25%), respectively. Transverse (r2)
water proton relaxivities were estimated from the correspond-
ing slopes, giving a value of 187.14 s−1 mM−1 for Eu−Gd (25−
75%). The r2 relaxivities were 90.16 and 78.66 s
−1 mM−1 for
Eu−Gd (50−50%) and Eu−Gd (75−25%), respectively. T1
and T2 map images (Figure 3a,b) show clear dose-dependent
contrast enhancement. Eu−Gd (50−50%) had the lowest r2/r1
value of 18.9, indicating its greater function as a T1 contrast
agent as compared to the other ratios. This, combined with the
moderate fluorescence at this ratio, we chose Eu−Gd (50−
50%) for the in vivo experiment.
To determine if NPs were able to accumulate and be
retained in the injured brain, we utilized a controlled cortical
impact (CCI) mouse model of TBI because of its high
reproducibility and characterization within the literature.47 We
used Eu−Gd (50−50%) for in vivo experiments because of
their combined fluorescence and magnetic characteristics.
Following catheter placement into the tail veins of the mice
and precontrast MRI scans, NPs (100 μL of 0.5 mM) were
injected, followed by a 100 μL chaser of phosphate-buffered
saline (PBS) to ensure that all NPs were injected. We
monitored NP uptake and retention kinetics through the
measurement of Ktrans, a permeation coefficient that reflects the
movement of a NP from the blood to the tissue, which we have
recently shown provides a robust measurement of NP uptake
and retention kinetics in TBI.22 A major advantage of Ktrans
modeling over other MRI methods for NP tracking such as
ΔR1 or ΔR2 mapping is that these other MRI methods cannot
distinguish the NP in the blood from the NP in the tissue
parenchyma.22 We found that the NPs rapidly accumulated
and were retained in the injured region of the brain, as shown
by higher Ktrans in the injury than in the surrounding brain
(Figure 4). The focal mean Ktrans value for Eu−Gd NP was
0.202 min−1. The contralateral mean Ktrans value of 0.00122
min−1 for NP was significantly lower (p < 0.001). Eu−Gd NPs
showed significantly high uptake in the focal injury than in the
contralateral brain, as expected with previous results assessing
the uptake of NP-based contrast agents into the brain
following TBI. This distinction in accumulation kinetics
between focal and contralateral regions illustrates the spatial
variability of the BBB dysfunction at early time points
following TBI, with much higher disruption occurring at the
site of the injury. This result also further supports the use of
NP-based therapeutics for passive targeting of the focal injury
in TBI as the NPs can rapidly accumulate in the injury and be
retained for a significantly longer time than small mole-
cules.19,22
To determine how NP uptake and retention kinetics
compare to blood kinetics, we assessed blood half-life
parameters from the MR image series used for Ktrans
Figure 2. (a) 2D Excitation−emission matrix of Eu−Gd nano-
particles. (b) Fluorescence intensity in different compositions of Eu−
Gd NPs.
Table 1. Properties of NPs
name size (nm)
ζ-
Potential R1 relaxivity (s
−1 mM−1) at 9.4 T quantum yield, ϕ molar extinction coefficient, ε (M−1 cm−1)
fluorescence lifetime
(ns)
Eu−Gd 13.5 −25.1 4.7697 0.33 2.15 × 103 1.6
Figure 3. (a) R1 relaxivity and T1 map images, (b) R2 relaxivity and T2
map images of Eu−Gd nanoparticles. Both relaxivity and map images
are changing with concentration variations of NPs.
Figure 4. NP uptake and retention kinetics in TBI. Ktrans maps
showing Eu−Gd NP accumulation and retention localization with
respect to damage, a plot of average Ktrans for all mice.
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measurements. Eu−Gd NPs showed the elimination profiles
(Table 2) in vivo with a t1/2,elim value of 26.53 min and a t1/2,dist
value of 1.84 min. This rapid distribution phase and relatively
short elimination half-life combined with our Ktrans measure-
ments that show the transfer of NPs from the blood into tissue
suggest that the NPs rapidly distribute into the injured region
of the brain and are retained there while NPs are quickly
removed from circulation likely through kidney clearance
because of their small size. This reduces the likelihood that
NPs are first taken up into circulating monocytes or peripheral
macrophages before subsequently being trafficked into the
injury, and that NPs are directly accumulating in the injury.
This is further supported by the evidence that first peripheral
immune cells that enter the injury are neutrophils at 24−48 h
postinjury.48,49 The small size of these NPs allowed for rapid
kidney clearance to minimize potential deleterious off-target
effects as compared to larger NPs with significantly longer
circulation times. While the area under the curve (AUC)
pharmacokinetic parameter is often used as an indicator of
exposure of the target tissue to small-molecule drugs, and
rapidly clearing ultrasmall NPs do not provide a very large
AUC, these ultrasmall NPs allow for prolonged exposure in the
target tissue because of their significantly reduced diffusivity as
compared to small-molecule drugs. Therefore, the NPs are
retained in the target tissue for extended periods as compared
to the elimination from blood, as we observed from our Ktrans
measurements (Figure 4), which are nearly 10-fold higher than
the small-molecule Gd−diethylenetriaminepentaacetic acid
(DTPA), from our previous22 results. In this way, ultrasmall
NPs provide the benefit of prolonged target tissue exposure
combined with short circulation time that minimizes exposure
to off-target tissues.
The overall rationale behind mixed Eu−Gd NPs was the
ability to visualize NP uptake kinetics using MRI because of
the contrast proved by Gd followed by fluorescence imaging of
tissue distribution because of the fluorescence signal provided
by Eu. This is important for better understanding the brain
delivery.29 We observed the signal from Eu−Gd NPs in brain
slices using an A4 filter that has an excitation wavelength at
360 ± 20 nm and emission wavelength at 470 ± 20 nm, which
fits perfectly with the excitation and emission wavelength of
Eu−Gd NP. The images (Figure 5) were taken in the
ipsilateral cortex since the ipsilateral cortex had the highest
Ktrans value, where the NPs were observed to accumulate and
be retained. From a fluorescence microscope, we observed that
the Eu−Gd NPs were found in the brain tissue and outside of
the blood vessel (Figure 5), whereas no signal was observed for
a control mouse injured brain that received no NP injection.
This further supports the idea that the NPs accumulate across
the disrupted BBB and are retained in the brain parenchyma.
3. CONCLUSIONS
We developed ultrasmall Eu−Gd NPs as a multimodal contrast
agent and tool for studying NP behavior in TBI. In this work,
we showed the influence of the reaction composition on the
magnetic relaxivity and fluorescence properties to find an ideal
combination of T1 contrast enhancement and fluorescence. In
a CCI mouse model of TBI, we found rapid accumulation and
retention of NPs within the injury using MRI analysis of Ktrans.
Additionally, the ultrasmall size of the NPs allowed for rapid
kidney clearance and relatively small AUC pharmacokinetic
parameter to reduce off-target exposure. Moreover, the cellular
localization of the NPs was determined by fluorescence
imaging to generate high spatial resolution information on
tissue and cellular distribution. Therefore, Eu−Gd NPs can be
used for combined MRI and fluorescence imaging to find
optimal NP properties that improve delivery to and especially
retention in TBI.
4. EXPERIMENTAL SECTION
4.1. Materials. Gadolinium chloride hydrate (GdCl3·
xH2O, 99.9%), europium(III) nitrate hydrate (Eu(NO3)3·
5H2O, 99.9%), triethylene glycol (TEG, 99%), sodium
hydroxide (NaOH), poly(ethylene glycol) diacid (Mn, 600),
ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride
(EDC, ≥98%), N-hydroxysuccinimide (NHS, 98%), and
molecular weight cutoff dialysis membranes (Flot-A-Lyzer,
20 kDa) were purchased from Sigma-Aldrich. Deionized water
in the experiments was obtained using a Millipore water
purification system. All other chemicals and solvents used in
this work were of high-performance liquid chromatography
(HPLC) grade.
4.2. Synthesis of Eu−Gd NPs. Eu(NO3)3·5H2O (1
mmol) and GdCl3·xH2O (1 mmol) were added into 30 mL
of triethylene glycol in a 100 mL three-necked flask. The
mixture was heated to 80 °C and magnetically stirred until the
two precursors were completely dissolved in the solvent. Then,
6 mmol NaOH was added and stirring was continued for 4 h at
Table 2. Pharmacokinetic Parameters of NPsa
NP type
distribution half-life
(t1/2,dist) (min) Kel,dist (min
−1)
elimination half-life
(t1/2,elim) (min) Kel,elim (min
−1)
area under concentration−time curve
(AUC) (min mM) refs
Eu−Gd 1.84 ± 0.62 0.409 ± 0.15 26.53 ± 4.95 0.027 ± 0.0045 76.6 ± 8.2 this
work
Gd−DTPA 4.01 ± 2.47 0.23 ± 0.11 15.70 ± 8.50 0.056 ± 0.023 6.6 ± 3.8 22
aData shown are averages ± standard deviations.
Figure 5. Fluorescence microscopy imaging of the ipsilateral cortex at
1 h after NP injection in Eu−Gd NP-treated CCI mice and mice that
did not receive NPs with 20× and 40× objective lens magnification.
Red is nucleus staining with propidium iodide, green is CD31
immunostaining of blood vessel, and blue is Eu−Gd NP. Scale bar is
10 μm.
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180 °C. To coat the hydrophobic MNPs, 4 mmol PEG diacid
was added and the reaction was continued with stirring for 12
h at 150 °C. After completely cooling, the synthesized
nanoparticles were washed three times using deionized water.
4.3. Characterization. A high-voltage transmission elec-
tron microscope (TEM) (Tecnai Osiris TM, 200 kV) was used
to measure particle diameters of PEG diacid-coated ultrasmall
Eu−Gd NPs. A copper grid (PELCO mesh size 400, TED
PELLA, INC.) covered with an amorphous carbon membrane
was placed onto a filter paper. Then, a sample solution diluted
in triple-distilled water was dropped over the copper grid using
a micropipette (Eppendorf, 2−20 μL). Core diameter
measurements from 71 MNPs were averaged to determine
the average core size. Dynamic light scattering (DLS) studies
of the NPs were conducted using a Malvern Instruments
Zetasizer Nano series instrument. Solutions of the NPs were
prepared in DPBS (pH 7.4) at a concentration of 0.05 mM.
The resulting solutions were filtered with 0.22 μm filters before
the measurement. The concentration of Eu and Gd was
determined using an inductively coupled plasma mass
spectrometer (ICP-MS) (Agilent 7500 cx). To determine
this, ∼1 mL of the NP solution was taken out and treated with
HNO3 to dissolve nanoparticles in solution completely. A
Fourier transform-infrared (FT-IR) spectrometer (Nicolet
AVATAR 380 FT-IR) was used to verify the surface coating.
To record the FT-IR absorption spectrum (400−4000 cm−1),
the powder sample was prepared.
4.4. Fluorescence Characterization. A microplate reader
(Synergy H1, BioTek) was used to record fluorescence spectra
of PEG diacid-coated ultrasmall Eu−Gd nanoparticles
dispersed in ethanol. To find out the maximum fluorescence
intensity, excitation wavelengths were used from 250 to 700
nm and emission wavelengths from 300 to 700 nm. After that,
fluorescence spectra were recorded for three different
compositions of Eu−Gd NPs at λex = 365 nm and λem = 450
nm. Quantum yields (Φs) of sample solution was estimated
using fluorescein as a standard.
Two-photon excited fluorescence intensity and lifetime
imaging was performed using the 740 nm mode-locked
femtosecond pulse train of a Spectra-Physics MaiTai Ti/S
laser on a Leica TCS SP8 MP multiphoton laser-scanning
confocal microscope (Leica Microsystems, Germany) equip-
ped with a Leica HC PL APO CS2 40×/1.3 NA oil immersion
objective. Blue and yellow nondescanned fluorescence were
separated using a 500 nm long-pass dichroic mirror and
isolated with HQ 460/80-2p and HQ 580/60-2p band-pass
filters (Chroma Technology, Bellows Falls, VT), respectively,
and detected with high-sensitivity super HyD detectors and a
time-correlated single-photon counting module (830 SPC,
Becker and Hickl, Berlin, Germany). The imaging field of view
was 276 × 276 μm2 (128 ×128 pixels) with a line scan rate of
400 Hz (dwell time of 19.5 μs pixel−1), a line average of 3, and
a total acquisition time of 120 s.
4.5. R1 and R2 Relaxivities and R1 and R2 Map Imaging
Measurements. Both R1 and R2 map images, as well as both
T1 and T2 relaxation times, were measured using a 9.4 T MRI
instrument (Varian 9.4 T) equipped with a 4 cm Millipede RF
imaging probe with triple-axis gradients (100 G cm−1 max). A
series of five aqueous solutions of different concentrations (0.5,
0.25, 0.125, 0.0625, and 0.03125 mM Ln) were prepared by
diluting each MRI solution with PBS. Then, both map images
and relaxation times were measured using these solutions. The
R1 and R2 relaxivities were then estimated from the slopes in
the plots of 1/T1 and 1/T2 versus NP concentration,
respectively. The measurement parameters for the fast spin-
echo T1 mapping sequence were as follows: the external MR
field (H) = 9.4 T, the temperature = 22 °C, the number of
acquisition (NEX) = 1, the field of view (FOV) = 25 × 25
mm2, the matrix size = 128 × 128 voxels, echo train length =
16, echo spacing = 8.1 ms, slice thickness = 2 mm, seven
repetition times (TRs) used in linear increments from 200−
2000 ms, and the echo time (TE) = 32.42 ms. The signal was
fit to the following equation using MATLAB to find T1
S S (1 e )T0
TR/ 1= − −
where S is signal for a given voxel and S0 is the signal of that
voxel at saturation. T2 mapping was carried out using a multi-
echo scan with the same parameters as the T1 scan with the
following exceptions: the number of echoes = 10, 10 TEs
linearly spaced from 10−100 ms, and TR = 3000 ms. T2
mapping was performed using Osirix and linear fitting followed
in MATLAB.
4.6. Controlled Cortical Impact (CCI) Mouse Model of
TBI. All animal work was approved by and done in accordance
with the University of NebraskaLincoln IACUC. We utilized
a severe controlled cortical impact (CCI) mouse model of
TBI.50 Six-week-old female C57BL/6J mice (Jackson Labo-
ratory, Bar Harbor, ME) were acclimated for 1 week prior to
any procedures. Anesthesia was induced with 3% isoflurane gas
via inhalation, and mice were affixed to a stereotaxic frame
(David Kopf Instruments, Tujunga, CA) using ear and bite
bars and anesthesia was maintained at ∼1.5%. The hair of the
scalp was removed with Nair (Church and Dwight Co., Inc.,
Princeton, NJ), and the scalp was disinfected with a betadine
scrub and isopropanol wipes. Lidocaine (0.05 mL of 5 mg
mL−1) and bupivacaine (0.05 mL of 0.3 mg mL−1) were
applied to the scalp, and buprenorphine SR (60 μL of 0.5 mg
mL−1) was injected subcutaneously. A midline incision
(approximately 1 cm) was made on the scalp over bregma.
Using a surgical drill, an approximately 2 mm burr hole was
made in the skull over the left frontoparietal cortex (2 mm
anterior and 2 mm left of lambda). A controlled cortical
impactor (Hatteras Instruments, Cary, NC) attached to the
stereotaxic frame was used to impact the brain normal to the
dura surface at a depth of 1.5 mm and a velocity of 4 m s−1
with a dwell time of 80 ms using a 2 mm convex tip. Bleeding
was controlled, and incisions were closed using tissue adhesive.
Mice were placed in a recovery cage on a heating pad and
monitored until awake prior to transfer to the imaging room. A
total of three mice were used for these experiments.
4.7. Ktrans MRI Method for In Vivo Imaging. Animal
imaging was performed using the same MRI system used for R1
and R2 assessments. All imaging studies were also approved by
the University of NebraskaLincoln IACUC. Mice were
induced and maintained using approximately 1.5% isoflurane
with adjustments made to maintain the breathing rate between
40 and 80 breaths per minute. Ktrans imaging to determine NP
accumulation and retention in TBI was performed similarly to
our previously published work.22 Precontrast gradient echo
scans were performed with flip angles (FAs) of 10 and 30° with
the following parameters: TR = 54.24 ms, TE = 2.73 ms, data
matrix = 128 × 128, 10 slices each with a field of view = 20 ×
20 × 1 mm3, and 5 averages for a scan time (temporal
resolution) of 34 s. Mice were injected with 100 μL of PBS
containing 0.5 mM Ln via tail vein catheter, followed by 100
μL of PBS flush to assure the administration of all contrast into
ACS Omega http://pubs.acs.org/journal/acsodf Article
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the animal. Postcontrast gradient echo scans all used a FA of
30° with the same parameters as listed above. The serial
acquisition was performed for 1 h following the injection
resulting in about 100 postcontrast scans per animal. R1
mapping was performed using the variable flip angle method
based on the following equation51
S S
E E
sin( ) tan( )
M (1 )SPGR SPGR 1 0 1α α
= + −
where SSPGR is signal intensity, α is FA, E1 is exp(TR/T1), and
M0 is a proportionality factor related to longitudinal magnet-
ization. E1 describes the linear relationship between the two
signal intensity ratios, taking the slope, m, of that line enables
calculation of T1 as
T
TR
mln( )1
= −
Concentration maps were then generated by the comparison
of baseline R1 maps with postcontrast R1 maps using the
following equation
C t
R t R t
r
( )
( ) ( )1 1 0
1
=
−
where C is the concentration at time t, R1(t) is the postcontrast
R1value at t, R1(t0) is baseline R1, and r1 is the relaxivity of the
contrast agent. Ktrans, the contrast extravasation rate constant,
mapping was then performed using a reference region (RR)
model derived from the extended Tofts’ model52
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where CTOI and CRR are concentrations in the tissue of interest
(TOI) and the RR, respectively, Ktrans,TOI and Ktrans, RR are Ktrans
in the TOI and RR, respectively, and ve,TOI and ve,RR are
extravascular−extracellular volume fractions for the TOI and
RR, respectively. Muscle tissue from within the FOV was used
in all animals. MATLAB was used to execute a least-squares
curve fitting routine to calculate Ktrans for each voxel in the
brain. Pharmacokinetic parameters were determined from
blood concentration profiles determined from the MR images
used for Ktrans mapping following our previously reported
procedures.22 Briefly, regions of interest (ROIs) were selected
in either carotid artery of concentration map images and used
to calculate blood half-life and elimination constants from the
1 h series of imaging.
4.8. Fluorescence Imaging. A fluorescence microscope
(Leica DMI3000B, Leica Biosystems) was used to take the
fluorescence image of mice brain. Mice were euthanized
immediately following the MR imaging protocol via 4%
paraformaldehyde perfusion under anesthesia, and the brain
tissue was collected, trimmed, and postfixed in 4%
paraformaldehyde in Dulbecco’s phosphate-buffered saline
(DPBS, Thermo Fisher Scientific, Waltham, MA) for 24 h
followed by 30% sucrose in DPBS for 3 days at 4 °C. The
brains were then embedded in an optimal cutting temperature
(OCT, Fisher Scientific, Waltham, MA) compound, frozen on
dry ice, and stored at −80 °C. The brains were sliced coronally
at a thickness of 15 μm with a cryotome (Leica Biosystems,
Wetzlar, Germany). Sections were washed with DPBS to
remove excess OCT. The brain slices were blocked with 3%
normal donkey serum, 0.3% Triton X-100, and 0.1% sodium
azide in DPBS. The primary and secondary antibodies (Ab)
were diluted in the blocking buffer. The brain sections were
incubated with rat primary Ab against CD31 (1:250, ab56299,
Abcam, Cambridge, U.K.) for 2 days at 4 °C then washed with
blocking buffer three times for 5 min each before being
incubated with a 1:250 dilution of goat secondary Ab against
rat AF488 (ab150158, Abcam) for 2 h at room temperature.
The brain sections were again washed with the blocking buffer
three times for 5 min each before being stained with 1:1000
dilution of propidium iodide for 15 min, washed with DPBS
two times for 5 min each, rinsed with DI water, and preserved
with ProLong Gold Antifade Mountant (Thermo Fisher
Scientific). The excitation and emission wavelength were
used to observe NPs at 360 ± 20 and 470 ± 20 nm,
respectively. CD31 and propidium iodide were observed under
488 and 555 nm filters, respectively. The objective
magnifications used for the imaging were 20× and 40×.
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